Stem Cell Therapeutics Corp. Announces Filing of Preliminary Short Form Base Shelf Prospectus

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SSS" or "Stem Cell
Therapeutics") is pleased to announce that it filed today a preliminary short
form base shelf prospectus (the "Prospectus") with the securities commissions in
each of the provinces of British Columbia, Alberta, Manitoba, Ontario and Nova
Scotia. The Prospectus, when made effective, will allow Stem Cell Therapeutics
to make offerings of common shares, warrants, or units for initial aggregate
proceeds of up to $15 million during the next 25 months to potential purchasers
in said provinces.


As previously announced, Stem Cell Therapeutics expects that it will need to
fund ongoing research and development, working capital and general corporate
activities which may include Stem Cell Therapeutics' clinical trial programs.


The Prospectus is expected to provide Stem Cell Therapeutics with a flexible and
efficient approach for completing future financings for research initiatives and
development.


A copy of the preliminary short form base shelf prospectus may be obtained from
the SEDAR website at www.sedar.com or from Stem Cell Therapeutics upon request
by email at [e-mail], by mail at Suite 500, 255 5th Ave. SW,
Calgary, AB T2P 3G6 or by telephone at 403.245.5495 ext. 221.


This news release shall not constitute an offer to sell nor the solicitation of
an offer to buy nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of any such
jurisdiction.


About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public
biotechnology company (TSX VENTURE:SSS) focused on the development and
commercialization of drug-based therapies to treat central nervous system
diseases. Stem Cell Therapeutics is a leader in the development of therapies
that utilize drugs to stimulate a patient's own resident stem cells. Stem Cell
Therapeutics' programs aim to repair brain and nerve function lost due to
disease or injury. The Stem Cell Therapeutics' extensive patent portfolio of
owned and licensed intellectual property supports the potential expansion into
future clinical programs in numerous neurological diseases such as traumatic
brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and
ALS.


These securities have not been registered under the United States Securities Act
of 1933, as amended, or the securities laws of any state, and may not be offered
or sold within the United States or to, or for the account or benefit of U.S.
persons unless an applicable exemption from U.S. registration requirements is
available.


Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.